Trium Capital LLP Ngm Biopharmaceuticals Inc Transaction History

Trium Capital LLP

  • $350 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$1.17 - $1.92 $1.14 Million - $1.88 Million
977,965 New
977,965 $1.56 Million

Others Institutions Holding NGM

# of Institutions
5
Shares Held
2.6M
Call Options Held
300
Put Options Held
0
View Full List

About NGM BIOPHARMACEUTICALS INC

NGM Quotes by TradingView
  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Trium Capital LLP Portfolio

Follow Trium Capital LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trium Capital LLP, based on Form 13F filings with the SEC.

News

Stay updated on Trium Capital LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email